StockNews.com Initiates Coverage on vTv Therapeutics (NASDAQ:VTVT)

Equities research analysts at StockNews.com initiated coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a research note issued on Thursday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners assumed coverage on shares of vTv Therapeutics in a research note on Monday, December 9th. They set a “buy” rating and a $35.00 price target on the stock.

vTv Therapeutics Stock Performance

Shares of NASDAQ VTVT opened at $17.21 on Thursday. The stock’s 50-day simple moving average is $17.19 and its 200-day simple moving average is $15.49. The firm has a market capitalization of $54.90 million, a PE ratio of -3.80 and a beta of 1.07. vTv Therapeutics has a fifty-two week low of $12.12 and a fifty-two week high of $29.19.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings data on Thursday, March 20th. The biotechnology company reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.32. The company had revenue of $0.02 million for the quarter.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. FMR LLC purchased a new stake in vTv Therapeutics in the third quarter valued at approximately $2,402,000. JPMorgan Chase & Co. purchased a new position in shares of vTv Therapeutics during the fourth quarter worth approximately $25,000. Finally, Geode Capital Management LLC increased its holdings in shares of vTv Therapeutics by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock valued at $158,000 after acquiring an additional 1,327 shares during the period. Hedge funds and other institutional investors own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.